FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379650147> ?p ?o ?g. }

• W4379650147 endingPage "1378" @default.
• W4379650147 startingPage "1377" @default.
• W4379650147 abstract "Background Current and previous EULAR recommendations (1,2) suggest using JAK-inhibitors (JAKis) for treating Rheumatoid Arthritis (RA). However, little is known about differences of patients who are JAK-inhibitors (JAKis) naïve and patients who have already experienced at least one JAKi. Objectives To analyse differences between JAK-naïve and JAKis not naive patients in a real life setting. Methods All patients with RA on JAKis were prospectively followed up for 12 months in this multicentric study conducted in 23 centres. For each patient, the following variables were recorded: sex, age, disease duration at JAKi prescription, smoking, BMI, comorbidities, positive RF/ACPA, DAS28-ESR at baseline, 6 and 12 months, cDMARDs and prednisone at baseline, JAKis discontinuation, JAK-naïve. Statistics were performed by R (2022.12.0). Results 864 patients were included ( Table 1 ). Among them, 731 (84.60%) were JAKis naïve, whereas 122 (14.12%) were not naïve (missing data in 11-1.27%-patients). 473 (55.22%) patients were treated with baricitinib (JAK-naïve were 412, 87.3%), 213 (24.6%) with tofacitinib (JAKis-naïve 187, 87.79%), 111 (12.84%) with upadacitinib (JAKis-naïve 78.37%) and 62 (7.17%) with filgotinib (JAKis-naïve 72.58%). Significant differences between JAKis-naïve and not naïve were found for hypercholesterolemia (p=0.04), hypertension (p=0.02), previous cancer (p<0.001), disease duration (p<0.001), line of treatment (p<0.001). No difference was found for JAKis discontinuation (p=0.13) (Table 1). Conclusion Our data suggest that line of treatment and disease duration result higher in JAKis not naive compared to naïve ones. Notably, JAKis naïve and not naïve did not differ regarding drug discontinuation, suggesting a similar retention rate irrespective of previous JAKis. References [1] Smolen JS, et al. Ann Rheum Dis 2020. [2] Smolen JS, et al. Ann Rheum Dis 2023. Table 1. Differences between JAKis naïve and not naïve patients Total Total (N=864) JAKis naive (N=731) JAKis not naïve (N=122) P value N (% ) N (% ) N(% ) Mean age at baseline (SD) (N=852) 58.83 (12.87) 58.54 (12.92) 60.61 (12.45) 0.10 Females (N=853) 668 (78.31) 564 (77.15) 104 (85.25) 0.05 Mean BMI (Kg/cm 2 ) (SD) (N=616) 25.15 (3.77) 25.18 (3.62) 25.02 (4.46) 0.68 Smoking (N=788) 0.13 Yes 150 (19.03) 135 (19.97) 15 (13.39) No 496 (62.94) 425 (62.87) 71 (63.39) Former 142 (18.02) 116 (17.16) 26 (23.31) Positive RF (N=800) 527 (65.89) 444 (64.91) 83 (71.55) 0.16 Positive ACPA (N=787) 491 (62.39) 411 (61.43) 80 (67.80) 0.19 Diabetes (N=760) 68 (8.95) 56 (8.78) 12 (9.84) 0.71 Hypertension (N=761) 297 (39.03) 238 (37.25) 59 (48.36) 0.02 Hypercholesterolemia (N=759) 195 (25.36) 155 (24.29) 40 (33.06) 0.04 Previous MACE (N=758) 47 (6.20) 39 (6.13) 8 (6.56) 0.86 Previous cancer (N=760) 42 (5.52) 39 (6.10) 3 (2.48) <0.001 Disease duration (months), (median, IQR) (N=844) 76 (29-155) 71 (24-142.50) 142 (69-226) <0.001 Mean DAS28-ESR at baseline (SD) (N=736) 5.29 (1.06) 5.27 (1.09) 5.40 (0.89) 0.22 cDMARDs at baseline (N=771) 280 (36.31) 235 (36.21) 45 (36.89) 0.88 PDN at baseline (N=438) 438 (50.69) 368 (57.38) 70 (56.79) 0.90 Median dosage (IQR) of PDN (mg/day) (N= 438) 5 (4.00-5.00) 2.50 (0.00-5.00) 4.00 (0.00-5-00) 0.08 Line of JAKis treatment (N=853) <0.001 1^ 244 (28.60) 244 (33.38) 0 (0.00) 2^ 211 (24.74) 207 (28.32) 4 (3.28) 3^ 175 (20.63) 172 (23.53) (3.28) 4^ 109 (12.78) 56 (7.66) 53 (3.44) 5^ 65 (7.62) 32 (4.38) 33 (27.05) 6^ 28 (3.28) 12 (1.64) 6 (13.11) 7^ 12 (1.41) 6 (0.82) 6 (4.92) 8^ 3 (0.35) 1 (0.14) 2 (1.64) 9^ 2 0.23) 1 (0.14) 1 (0.82) 10^ 3 (0.35) 0 (0.00) (2.46) Patients who discontinued JAKis (N=853) 192 (22.51) 158 (21.61) 34 (27.87) 0.13 SD: standard deviation; BMI: Body Mass Index; RF: Rheumatoid Factor; ACPA: Autoantibodies against citrullinated proteins; MACE: Major cardiovascular events; PDN: prednisone; IQR: interquartile range; DAS28-ESR: Disease Activity Score-28 for Rheumatoid Arthritis with ESR; cDMARDs: conventional Disease-modifying antirheumatic agents; JAKis: JAK inhibitors. Acknowledgements: NIL. Disclosure of Interests Maddalena Larosa: None declared, Andrea Becciolini: None declared, Elena Bravi: None declared, Dario Camellino Speakers bureau: Abiogen, GSK, Paid instructor for: Mylan, Ilaria Platé: None declared, eugenio arrigoni: None declared, Francesca Ometto: None declared, Eleonora Di Donato: None declared, Giuditta Adorni: None declared, Gianluca Lucchini: None declared, Daniele Santilli: None declared, Alessandra Bezzi: None declared, Maria Cristina Focherini: None declared, Fabio Mascella: None declared, Vincenzo Bruzzese: None declared, Palma Scolieri: None declared, Simone Parisi: None declared, Enrico Fusaro: None declared, Maria Chiara Ditto: None declared, Viviana Ravagnani: None declared, Gilda Sandri: None declared, Carlo Salvarani: None declared, Marta Priora: None declared, Marino Paroli: None declared, rosalba caccavale: None declared, Romina Andracco: None declared, Natalia Mansueto: None declared, Matteo Colina: None declared, Massimo Reta: None declared, Olga Addimanda: None declared, Alberto Lo Gullo: None declared, elisa visalli: None declared, Rosario Foti: None declared, Giorgio Amato: None declared, Francesco De Lucia: None declared, antonella farina: None declared, Francesco Girelli: None declared, Patrizia Del Medico: None declared, Aldo Molica Colella: None declared, Veronica Franchina: None declared, Francesco Molica Colella: None declared, Federica Lumetti: None declared, Aurora Ianniello: None declared, Valeria Nucera: None declared, Rosetta Vitetta: None declared, Alessia Fiorenza: None declared, Guido Rovera: None declared, Alessandro Volpe: None declared, Giulio Ferrero: None declared, Antonio Marchetta: None declared, Simone Bernardi: None declared, Gerolamo Bianchi: None declared, Alarico Ariani: None declared." @default.
• W4379650147 created "2023-06-08" @default.
• W4379650147 creator A5001415419 @default.
• W4379650147 creator A5006222773 @default.
• W4379650147 creator A5007177217 @default.
• W4379650147 creator A5008562624 @default.
• W4379650147 creator A5009797024 @default.
• W4379650147 creator A5011017751 @default.
• W4379650147 creator A5011583819 @default.
• W4379650147 creator A5014170657 @default.
• W4379650147 creator A5014317263 @default.
• W4379650147 creator A5016160868 @default.
• W4379650147 creator A5017440327 @default.
• W4379650147 creator A5018262312 @default.
• W4379650147 creator A5022555111 @default.
• W4379650147 creator A5024433998 @default.
• W4379650147 creator A5025745099 @default.
• W4379650147 creator A5027608188 @default.
• W4379650147 creator A5029436256 @default.
• W4379650147 creator A5033392497 @default.
• W4379650147 creator A5033612996 @default.
• W4379650147 creator A5034643922 @default.
• W4379650147 creator A5037811380 @default.
• W4379650147 creator A5040022818 @default.
• W4379650147 creator A5040272591 @default.
• W4379650147 creator A5040385086 @default.
• W4379650147 creator A5041863389 @default.
• W4379650147 creator A5044774777 @default.
• W4379650147 creator A5046989930 @default.
• W4379650147 creator A5048532746 @default.
• W4379650147 creator A5050331036 @default.
• W4379650147 creator A5050485006 @default.
• W4379650147 creator A5051868680 @default.
• W4379650147 creator A5052431264 @default.
• W4379650147 creator A5055089221 @default.
• W4379650147 creator A5056725531 @default.
• W4379650147 creator A5058223764 @default.
• W4379650147 creator A5058511059 @default.
• W4379650147 creator A5061497790 @default.
• W4379650147 creator A5064660795 @default.
• W4379650147 creator A5066512158 @default.
• W4379650147 creator A5071017744 @default.
• W4379650147 creator A5074859601 @default.
• W4379650147 creator A5075546098 @default.
• W4379650147 creator A5076292590 @default.
• W4379650147 creator A5077030657 @default.
• W4379650147 creator A5078087305 @default.
• W4379650147 creator A5079843499 @default.
• W4379650147 creator A5080792042 @default.
• W4379650147 creator A5081902640 @default.
• W4379650147 creator A5082704027 @default.
• W4379650147 creator A5084751395 @default.
• W4379650147 creator A5087298739 @default.
• W4379650147 creator A5088924811 @default.
• W4379650147 creator A5089394672 @default.
• W4379650147 date "2023-05-30" @default.
• W4379650147 modified "2023-09-25" @default.
• W4379650147 title "AB0386 DIFFERENCES BETWEEN JAKIS-NAIVE AND JAKIS-NOT NAIVE PATIENTS IN A REAL LIFE CLINICAL SETTING: DATA FROM AN PROSPECTIVE MULTICENTRIC ITALIAN STUDY." @default.
• W4379650147 doi "https://doi.org/10.1136/annrheumdis-2023-eular.3992" @default.
• W4379650147 hasPublicationYear "2023" @default.
• W4379650147 type Work @default.
• W4379650147 citedByCount "0" @default.
• W4379650147 crossrefType "journal-article" @default.
• W4379650147 hasAuthorship W4379650147A5001415419 @default.
• W4379650147 hasAuthorship W4379650147A5006222773 @default.
• W4379650147 hasAuthorship W4379650147A5007177217 @default.
• W4379650147 hasAuthorship W4379650147A5008562624 @default.
• W4379650147 hasAuthorship W4379650147A5009797024 @default.
• W4379650147 hasAuthorship W4379650147A5011017751 @default.
• W4379650147 hasAuthorship W4379650147A5011583819 @default.
• W4379650147 hasAuthorship W4379650147A5014170657 @default.
• W4379650147 hasAuthorship W4379650147A5014317263 @default.
• W4379650147 hasAuthorship W4379650147A5016160868 @default.
• W4379650147 hasAuthorship W4379650147A5017440327 @default.
• W4379650147 hasAuthorship W4379650147A5018262312 @default.
• W4379650147 hasAuthorship W4379650147A5022555111 @default.
• W4379650147 hasAuthorship W4379650147A5024433998 @default.
• W4379650147 hasAuthorship W4379650147A5025745099 @default.
• W4379650147 hasAuthorship W4379650147A5027608188 @default.
• W4379650147 hasAuthorship W4379650147A5029436256 @default.
• W4379650147 hasAuthorship W4379650147A5033392497 @default.
• W4379650147 hasAuthorship W4379650147A5033612996 @default.
• W4379650147 hasAuthorship W4379650147A5034643922 @default.
• W4379650147 hasAuthorship W4379650147A5037811380 @default.
• W4379650147 hasAuthorship W4379650147A5040022818 @default.
• W4379650147 hasAuthorship W4379650147A5040272591 @default.
• W4379650147 hasAuthorship W4379650147A5040385086 @default.
• W4379650147 hasAuthorship W4379650147A5041863389 @default.
• W4379650147 hasAuthorship W4379650147A5044774777 @default.
• W4379650147 hasAuthorship W4379650147A5046989930 @default.
• W4379650147 hasAuthorship W4379650147A5048532746 @default.
• W4379650147 hasAuthorship W4379650147A5050331036 @default.
• W4379650147 hasAuthorship W4379650147A5050485006 @default.
• W4379650147 hasAuthorship W4379650147A5051868680 @default.
• W4379650147 hasAuthorship W4379650147A5052431264 @default.
• W4379650147 hasAuthorship W4379650147A5055089221 @default.
• W4379650147 hasAuthorship W4379650147A5056725531 @default.
• W4379650147 hasAuthorship W4379650147A5058223764 @default.

• next